

**ASX ANNOUNCEMENT**

**MAJOR USA PATENT GRANTED**

**26<sup>th</sup> August 2008, Sydney, Australia;** Medical Therapies received notification that the United States Patent and Trademark Office has granted the Company's patent application titled ***"Agents Comprising Midkine or an Inhibitor Thereof as Active Ingredient"***. The Company has now been formally issued with the patent which has been allocated the number 7,390,491.

This is a significant therapeutic patent in the Company's portfolio and relates to the treatment of inflammatory diseases by Midkine and/or its inhibitors. It also covers key disease interests in the Company's product development plan.

This patent has previously been granted and issued in other key territories including Europe and Australia, providing broad global coverage for the treatment of inflammatory diseases.

Midkine modulates biological functions such as apoptosis, cell growth and cell migration and as a consequence it presents an important therapeutic, diagnostic and theragnostic target.

Throughout the world a total of 51 patents exist in relation to Midkine. Medical Therapies, with its 26 patent and patent application families, has the largest portfolio globally of intellectual property around Midkine and anti-midkine compounds.

**About Medical Therapies Limited (ASX: MTY):**

Medical Therapies Limited is a biotechnology company listed on the Australian Stock Exchange. The Company is the owner of the largest intellectual property portfolio around midkine, including several therapeutic uses of the protein and a large number of anti-midkine antibodies and nucleotides. Midkine is a native protein expressed during early cancer formation as well as at the onset of inflammatory processes. Midkine is a significant therapeutic and diagnostic target and Medical Therapies is committed to the commercialisation of these exciting drug candidates. In addition to its in-house therapeutic program Medical Therapies is actively seeking partnership opportunities for its non-core therapeutic and diagnostic assets.

For further information visit [www.medicaltherapies.com.au](http://www.medicaltherapies.com.au) or contact:

Maria Halasz  
CEO  
M +61 416 008 413

**Investment in biotechnology companies**

There are a number of inherent risks associated with the research, development and commercialisation of pharmaceutical products. Investment in companies specialising in these activities carry specific risks which are different to those associated with trading and manufacturing businesses. As such, these companies should be regarded as highly speculative. Medical Therapies recommends that investors seek professional advice before making an investment in its shares.